Table 1 |
||||
|
Baseline clinical and biochemical characteristics of 7074 Chinese Type 2 diabetic patients without clinical evidence of coronary heart disease and heart failure at enrollment during 5.52 years of follow-up in the training dataset and the test dataset |
||||
| Training dataset (n = 3456) |
Test dataset (n = 3611) |
|||
|
|
||||
| median or % |
IQR* |
median or % |
IQR* |
|
|
|
||||
| Male Gender |
45.2% |
45.6% |
||
| Smoking status |
||||
| Current smoker |
20.4% |
20.7% |
||
| Ex smoker |
13.1% |
13.8% |
||
| Age (year) |
57 |
21 |
57 |
21 |
| Body mass index (kg/m2) |
24.6 |
4.8 |
24.7 |
5.0 |
| Years of diagnosed diabetes |
5 |
10 |
5 |
9 |
| Systolic BP (mmHg) |
134 |
27 |
134 |
28 |
| Diastolic BP (mmHg) |
76 |
13 |
76 |
15 |
| HbA1c (%) |
7.3 |
2.2 |
7.4 |
2.2 |
| Blood haemoglobin (g/L) |
13.8 |
2.1 |
13.8 |
2.2 |
| White blood cell count (109/counts/L) |
7.0 |
2.4 |
7.0 |
2.4 |
| Spot urinary albumin creatinine ratio (mg/mmol) |
2.0 |
10.1 |
2.0 |
10.0 |
| eGFR (ml min-1 1.73 m-2) ξ |
104.9 |
43.0 |
104.9 |
43.5 |
| LDL-C (mmol/l) |
3.13 |
1.24 |
3.11 |
1.29 |
| HDL-C (mmol/l) |
1.24 |
0.45 |
1.25 |
0.45 |
| Triglyceride (mmol/L) |
1.37 |
1.08 |
1.39 |
1.12 |
| Non-HDL cholesterol (mmol/L) |
3.87 |
1.40 |
3.87 |
1.43 |
| Drug use at baseline |
||||
| On diet treatment |
10.2% |
9.9% |
||
| Use of oral anti-diabetic drugs |
61.0% |
60.6% |
||
| Use of anti-hypertensive drugs |
34.1% |
33.3% |
||
| Use of insulin |
17.5% |
17.4% |
||
| Use of LLD§ |
11.6% |
13.2% |
||
| Use of ACEI or ARB¶ |
20.4% |
20.1% |
||
| Complications at baseline |
||||
| Retinopathy |
25.4% |
27.4% |
||
| Sensory neuropathy |
26.0% |
25.7% |
||
| Peripheral arterial disease |
5.8% |
5.9% |
||
| History of stroke |
3.6% |
4.4% |
||
| Complications during follow-up |
||||
| Coronary heart disease before heart failure during follow-up |
4.4% |
4.4% |
||
| Heart failure hospitalisation during follow-up |
3.8% |
4.0% |
||
| Death during follow-up |
9.4% |
9.9% |
||
|
*, Median (IQR = interquartile range); ξ, eGFR = estimated glomerular filtration rate; §, LLD, lipid lowering drugs; ¶, ACEI, Angiotensin-converting enzyme inhibitors and ARB for angiotensin II receptor blockers. | ||||
Yang et al. Cardiovascular Diabetology 2008 7:9 doi:10.1186/1475-2840-7-9 |
||||
